Subtype
Adult-Type Diffuse Glioma
CI-CAN-00009389Explore in graph →
510 active trials2 approved drugs70 evidence items
- OncoTree
- ADIFG
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00009389Explore in graph →
Clinical trials
1,869 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (296)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01903330 | ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme | unknown | Phase 2 | 84 | Epitopoietic Research CorporationINDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT06353360 | TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma. | unknown | Phase 2 | 30 | Jiangsu Healthy Life Innovation Medical Technology Co., LtdINDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05638451 | Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients | unknown | Phase 2 | 30 | Zhujiang HospitalOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT04600817 | A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT) | unknown | Phase 2 | 160 | TJ Biopharma Co., Ltd.INDUSTRY | 2 | Apr 15, 2024 | clinicaltrials |
| NCT04573192 | A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression(GLIOSTAR) | unknown | Phase 1 / Phase 2 | 142 | Philogen S.p.A.INDUSTRY | 4 | Apr 8, 2024 | clinicaltrials |
| NCT03548571 | Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy(DEN-STEM) | unknown | Phase 2 / Phase 3 | 60 | Oslo University HospitalOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06279767 | Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma | unknown | Phase 1 / Phase 2 | 27 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05163080 | SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)(SURVIVE) | unknown | Phase 2 | 247 | MimiVax, LLCINDUSTRY | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06186440 | Cisplatin Plus Temozolomide Compared With Temozolomide in Patients With MGMT Promotor Unmethylated Glioblastoma(Glioblastoma) | unknown | Phase 1 / Phase 2 | 60 | Zhongnan HospitalOTHER | 0 | Jan 2, 2024 | clinicaltrials |
| NCT05820191 | B-amyloid as a Marker for GBM Bioimaging | unknown | Phase 2 | 3 | Universidad Central del CaribeOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT03951142 | Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan Study(ImPRESS) | unknown | Phase 2 | 165 | Kyrre Eeg EmblemOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT04671459 | TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-Thyrosine(TaRRGET) | unknown | Phase 2 | 40 | Prof. Franciszek Lukaszczyk Memorial Oncology CenterOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT05191784 | GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients | unknown | Phase 2 | 20 | Genexine, Inc.INDUSTRY | 1 | Jun 12, 2023 | clinicaltrials |
| NCT04223999 | Improving Tumor Treating Fields Treatment for Brain Cancer Patients With Skullremodeling Surgery (Neurosurgery)(OptimalTTF-2) | unknown | Phase 2 | 70 | Anders Rosendal KorshøjOTHER | 1 | Jun 6, 2023 | clinicaltrials |
| NCT02137759 | MRSI to Predict Response to RT/TMZ ± Belinostat in GBM | unknown | Phase 2 | 29 | Emory UniversityOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05694416 | Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Glioblastoma | unknown | Phase 2 | 60 | Zhongnan HospitalOTHER | 0 | Jan 23, 2023 | clinicaltrials |
| NCT04840069 | Radiotherapy Planning Using Fluciclovine PET in Patients With Newly Diagnosed Glioblastoma | unknown | Phase 2 | 100 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT04077866 | B7-H3 CAR-T for Recurrent or Refractory Glioblastoma | unknown | Phase 1 / Phase 2 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 28, 2022 | clinicaltrials |
| NCT05663125 | LITT Combined With Early Use of Temozolomide for Recurrent Glioblastomas | unknown | Phase 1 / Phase 2 | 10 | Beijing Tiantan HospitalOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT03750071 | VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma | unknown | Phase 1 / Phase 2 | 30 | Vaximm GmbHINDUSTRY | 1 | Oct 20, 2022 | clinicaltrials |
| NCT05447195 | Phase 2 Study of CAN008 in Subjects With GBM | unknown | Phase 2 | 117 | CANbridge Life Sciences Ltd.INDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT03400917 | Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma | unknown | Phase 2 | 55 | Aivita Biomedical, Inc.INDUSTRY | 1 | Dec 16, 2021 | clinicaltrials |
| NCT04888611 | Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma | unknown | Phase 2 | 40 | Huashan HospitalOTHER | 1 | Nov 30, 2021 | clinicaltrials |
| NCT05131711 | Combination of Stereotactic Radiosurgery and Enhanced Immunotherapy for Recurrent Glioblastomas(inSituVac2)(CSREIG)(CSREIG) | unknown | Phase 1 / Phase 2 | 60 | Beijing Tiantan HospitalOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05033587 | Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma. | unknown | Phase 2 | 28 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT03008148 | Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM | unknown | Phase 2 / Phase 3 | 288 | Johnpro Biotech, Inc.INDUSTRY | 1 | May 11, 2021 | clinicaltrials |
| NCT04874506 | MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM) | unknown | Phase 2 | 55 | Matrix Biomed, Inc.INDUSTRY | 1 | May 5, 2021 | clinicaltrials |
| NCT03025893 | A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme(STELLAR) | unknown | Phase 2 / Phase 3 | 100 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT04772846 | Chloroquine for Glioblastoma. | unknown | Phase 1 / Phase 2 | 60 | Egyptian Medical SyndicateOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT04725214 | Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma | unknown | Phase 2 | 33 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT04715620 | Niraparib Combined With Radiotherapy in rGBM | unknown | Phase 2 | 30 | Tianjin Huanhu HospitalOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT04674527 | Pilot Study of Elemene in Treating Patients With Refractory Glioblastoma | unknown | Phase 2 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 19, 2020 | clinicaltrials |
| NCT04583020 | Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma | unknown | Phase 2 | 42 | Peking Union Medical College HospitalOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT04552977 | A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma | unknown | Phase 2 | 50 | Shandong Cancer Hospital and InstituteOTHER | 0 | Sep 17, 2020 | clinicaltrials |
| NCT04547855 | Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen | unknown | Phase 2 | 54 | Yonggao MouOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT01567202 | Study of DC Vaccination Against Glioblastoma | unknown | Phase 2 | 100 | Huashan HospitalOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT04450160 | Trial of AEO in New Glioblastoma (GBM)(AEO) | unknown | Phase 2 | 80 | MetVital, Inc.INDUSTRY | 0 | Jun 29, 2020 | clinicaltrials |
| NCT04388033 | Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients. | unknown | Phase 1 / Phase 2 | 10 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 9, 2020 | clinicaltrials |
| NCT02715297 | Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent Glioblastoma(GlioCave/NOA17) | unknown | Phase 2 | 162 | Technical University of MunichOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT04224441 | Repurposing Chlorpromazine in the Treatment of Glioblastoma(RACTAC) | unknown | Phase 2 | 41 | Marco G Paggi, MD, PhDOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT04157478 | Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma | unknown | Phase 2 | 464 | People's Hospital of Guangxi Zhuang Autonomous RegionOTHER | 1 | Nov 12, 2019 | clinicaltrials |
| NCT04004975 | Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib | unknown | Phase 1 / Phase 2 | 50 | Shandong Cancer Hospital and InstituteOTHER | 1 | Jul 2, 2019 | clinicaltrials |
| NCT03916757 | V-Boost Immunotherapy in Glioblastoma Multiforme Brain Cancer(GBM) | unknown | Phase 2 | 20 | Immunitor LLCINDUSTRY | 1 | Apr 17, 2019 | clinicaltrials |
| NCT02209428 | A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas | unknown | Phase 2 | 54 | Huashan HospitalOTHER | 1 | Feb 21, 2019 | clinicaltrials |
| NCT03746288 | To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM) | unknown | Phase 2 | 60 | CANbridge Life Sciences Ltd.INDUSTRY | 0 | Nov 19, 2018 | clinicaltrials |
| NCT03607643 | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | unknown | Phase 1 / Phase 2 | 160 | Leaf Vertical Inc.INDUSTRY | 1 | Jul 31, 2018 | clinicaltrials |
| NCT02945826 | uPAR-PET/MRI in Glioblastoma Multiforme | unknown | Phase 2 | 35 | Rigshospitalet, DenmarkOTHER | 1 | Apr 10, 2018 | clinicaltrials |
| NCT03294486 | Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients(ONCOVIRAC) | unknown | Phase 1 / Phase 2 | 78 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT01759810 | Proteome-based Personalized Immunotherapy of Glioblastoma | unknown | Phase 2 / Phase 3 | 60 | NeuroVita ClinicOTHER | 1 | Oct 12, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Mar 5, 2025source: clinicaltrials